RxDoctor Payments Data

David Nguyen, MD

Interventional Pain Medicine · Pearland, TXNPI 1336137785

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,587 of the $11,560 with a category attached, or 74.3%. 15 manufacturers reported payments, led by Medtronic at 39.4% of the total. 2025 is the largest year on record at $4,828, more than ten times the $311 reported in 2020.

$11,560in general payments, 2019–2025

Across 177 payments — averaging $65.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Saluda Medical Americas, Inc.$3K
  • Stimwave Technologies Incorporated$910
  • Abbott$516
  • Nevro Corp.$502
  • Boston Scientific$382
  • plus $2K from 9 others
$117,369in research payments, 2019–2025

Across 6 payments — averaging $19,561 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astrazeneca UK Limited$70K
  • Genmab U.S., Inc.$48K

What the payments were for

  • Travel & lodging$2,95426%
  • Food & beverage$8,58774%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,560 in reported general payments places this provider in the 65th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$67,983
Medicare patients
68
Services billed
674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen728$18,906
Hydromorphone ErHydromorphone Hcl14$7,180
Lidocaine41$6,068
Gabapentin276$3,126
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen79$2,786
Pregabalin123$2,083
Acetaminophen-CodeineAcetaminophen With Codeine96$1,859
Morphine Sulfate ErMorphine Sulfate45$1,684
Diclofenac Sodium41$1,072
Naloxone Hcl16$1,070
Methocarbamol130$1,004
Baclofen59$919
Cyclobenzaprine Hcl124$850
Tizanidine Hcl82$575
Tramadol Hcl91$543

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Pearland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →